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Abstract
The GATA3 transcription factor is expressed in many tissues such as the immune system, kidney, brain, 
endometrium, and mammary epithelial cells. As such it must co-ordinate a diverse transcriptional program to 
achieve speciﬁ  c outcomes in different tissues. One of the most interesting questions raised is whether GATA3 
will be involved in the same pathways in every tissue or will be involved in distinct regulatory networks within 
different tissue types? While previous studies may imply the latter, with some known targets of GATA3 perhaps 
being speciﬁ  c to cell-type or tissue-type, the question has not been systematically addressed until now. With 
the advent of techniques such as co-expression meta-analysis a better understanding of the pathway partners 
of GATA3 can be obtained and speciﬁ  cally the partners within different tissue types can be found, yielding 
leads for future studies. Here, a recent technique of meta-analysis from the Oncomine database has been 
employed to probe this very question. Data obtained implies that GATA3 is involved in distinct pathways in 
different tissue types.
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Introduction
The GATA3 transcription factor has been studied intensively 
in the immune system, but has most recently been shown to 
be important in the context of breast cancer and the estrogen 
receptor α pathway.[1,2] These and many other studies have 
shown the power of linking breast cancer co-expressed gene 
datasets of GATA3 to its ability to play a putative role in 
the luminal A subtype of breast cancers, while also having a 
physiological role in normal breast epithelial cells. Recently, it 
has been proposed that GATA3 might act differently in different 
tissues.[3] As meta-analysis of GATA3 co-expressed genes in 
breast cancers, from the Oncomine database, yielded data that 
was analogous to previously known studies, it was possible that 
this technique could also be utilized to show tissue-specific (or 
common) pathways of GATA3.[4]
Consistent co-expression of genes has been shown to link their 
protein products to the same pathways, although it is impossible 
to determine the nature of this association (e.g., upstream, 
downstream, together in a complex) without further study. 
What this does generate, however, are rich leads into previously 
unknown or undefined areas for study. 
The Oncomine meta-analysis technique[4–6] was employed using 
various studies of different types (leukemia, lymphoma, brain, 
kidney, and prostate studies), all of which have been previously 
observed to show GATA3 expression. Co-expressed genes of 
GATA3 were then assessed within these cancer/tissue-types 
and are described below. Finally, the gene lists generated for 
individual analyses were compared to assess common co-
expressed genes over multiple tissues. Tentative results indicate 
that GATA3 may be involved in distinct pathways in different 
tissue-types, confirming the initial hypothesis. A prime example 
of this is the estrogen receptor alpha (ERα) pathway in breast 
cancer studies,[4] where ERα is the highest co-expressing gene 2 2
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with GATA3, whereas in the other cancer types investigated, 
this high level of co-expression was not evident, thereby 
indicating that the ERα pathway need not play a significant 
role for GATA3 in every situation.  
Co-expression Meta-analysis of Leukemia 
Studies
GATA3 expression has previously been observed in 
leukemia cells, however, the role GATA3 may play has 
not been intensively investigated, leaving a need for new 
knowledge.[7] The highest co-expressing gene with GATA3 in 
leukemia meta-analysis was the T-cell receptor (TCR) alpha 
locus (TRA@), in over 60% of studies [Additional File 1]. This 
is confirmation of a previous report that demonstrated GATA3 
binding to the TCR-alpha enhancer.[8] Similar to this, the TCR-
delta locus (TRD@) was also co-expressed with GATA3 and 
has also previously shown to be bound by GATA3.[9,10] Both 
of these results act as initial validation of the meta-analysis 
technique. As might be expected, there was an abundance of 
immunological co-expressed genes such as these. Interleukins 
and their receptors (IL32, IL27RA, IL2RB, IL10RA, IL7R and 
IL15), other T-cell receptors and associated factors (TRBC1, 
TRAT1, LAT, CD3D, CD3E, CD3G, TARP, ICOS, MAL, TRGV9, 
TRGC2 and PTCRA), and granzyme proteases (GZMA, GZMB, 
GZMK and GZMM) are just some notable examples of the many 
immune genes represented. 
As GATA3 has been intensively investigated in an immunological 
context for many years, especially with regard to T-cells, these 
data may help to shed light on the role GATA3 plays, albeit 
by implication via these co-expressed genes. For example, 
the granzyme proteases have been shown to be involved in 
cell-death pathways, regulated by cytotoxic T-cells and natural 
killer cells.[11]
Co-expression Meta-analysis of Lymphoma 
Studies
As lymphomas are also derived from the cells of the immune 
system, it is no surprise that the co-expressed genes with 
GATA3 have a significant overlap with those of the leukemias. 
For example, the interleukins and receptors (IL15, IL15RA, 
IL7R, IL2RB, IL32, IL1R1, IL3RA, IL1R2, IL18R1, IL13RA1 and 
IL10) show overlap with 4 of the 6 co-expressed for leukemias 
[Additional File 2]. 
Chemokines and receptors are also notably co-expressed 
with GATA3 in lymphomas (CXCL10, CXCR6, CXCL9, 
CXCL11, CXCL12 and CXCL13) as are the members of the 
STAT transcription family (STAT1, STAT3, STAT4, STAT5A 
and STAT5B). It is of interest that GATA3 has previously been 
observed to co-operate with STAT5A in naïve CD4 T-cells 
to prime towards a Th2 phenotype, emphasizing its role in 
differentiation.[12] 
Co-expression Meta-analysis of Brain Studies
GATA3 has been seen to be important in the development of 
the mammalian brain, with Gata3 -/- mice displaying severe 
brain and nervous system abnormalities.[13] GATA3 was also 
shown to be downstream of GATA2.[14,15] More recently, 
however, it was shown that the role of GATA3 in neonatal (i.e. 
post-development) mouse brain is limited.[16] 
It is possible that in conditions such as brain tumors the 
cancer will be in a de-differentiated state, thus expressing 
more developmental proteins such as GATA3. The highest co-
expressing gene with GATA3 in Oncomine brain studies was 
the Disco Interacting Protein 2, homolog C (DIP2C) [Additional 
File 3]. While this remains little-studied, it is interesting to 
note that dip2 is expressed in the mouse nervous-system.[17] Of 
interest, the neurofibromin 2 (NF2) gene is strongly expressed 
in the developing brain[18] and is involved in schwannomas[19] 
and is here also co-expressed with GATA3 in Oncomine brain 
studies. Whether GATA3 plays a role in schwannomas remains 
to be investigated. 
Co-expression Meta-analysis of Kidney Studies
The hypoparathyroidism, sensoneural deafness, and renal 
abnormality (HDR) syndrome in humans is linked to 
haploinsufficiency of GATA3.[20–22] GATA3 is also expressed 
in developing human and mouse kidneys.[23,24] Specifically, 
GATA3 was shown to be important for the development of the 
nephric duct.[25] These data show a requirement for GATA3 to 
be expressed within renal tissues. 
For meta-analysis, however, there were a limited number 
(9) of Oncomine renal studies with co-expressing 
genes for GATA3. Even so, many highly co-expressing 
genes were observed such as KCNJ1 (ROMK), which 
is seen with GATA3 in over half of these studies 
[Additional File 4]. ROMK, as might be expected by its 
function as a potassium channel, is important to kidney 
function.[26,27] Furthermore, GATA3 co-expressed with 
many other transporters (SLC7A8, SLC19A2, SLC12A1, 
SLC7A7, SLC27A2, SLC26A7, SLC29A2, SLC25A33, SCN3A, 
SCN2A, KCNK10, KCNJ15, KCNJ10, CLIC5, CLCNKA, 
CLCNKB, CACNG4, ATP1A1, ATP6V0A4 and AQP2), possibly 
implying a GATA3 pathway in the kidney. There was also 
a modest co-expression with renin (REN), which as part 
of the renin-angiotensin system is one of the key genes of 
the kidney. 3 3
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Co-expression Meta-analysis of Prostate 
Studies
The role of GATA3 in the prostate is the least studied of all 
tissues presented. In contrast, however, there were many 
(17) Oncomine studies with co-expressed genes for GATA3 
[Additional File 5]. In a recent study of candidate prostate 
cancer genes, GATA3 was identified and confirmed by 
immunohistochemistry.[28] This report showed that GATA3 
expression is normally low in normal prostate, perhaps 
explaining why it has not yet been studied to any significant 
degree. However, as Oncomine studies are based on cancer, 
the data presented here might be most useful in analysis of 
GATA3 in prostate cancer. GATA sites were also shown to 
be important for full induction of prostate-specific antigen 
(PSA) in LNCaP cells,[29] while a different antigen, the prostate 
stem cell antigen (PSCA) is co-expressed with GATA3 in the 
meta-analysis. 
As GATA3 is co-expressed with keratin 18 in breast cancers,[4] 
it is of interest that in prostate, GATA3 co-expressed with 
many other keratins (KRT5, KRT7, KRT13, KRT14, KRT15, 
KRT17, and KRT23). GATA3 was also co-expressed with 
transcription factors including p63 (TP63). The p63 protein 
is essential for the development of stratified epithelia 
in tissues such as the prostate and is highly expressed in 
proliferative epithelial stem cells.[30] GATA3 and p63 appeared 
to be overexpressed in urothelial cancers in a recent study 
combining microarrays and histochemistry, although this was 
not observed in prostate.[31] Other co-expressed transcription 
factors from the current meta-analysis include SMARCD3, 
SMAD3, PDLIM3, PDLIM4, NR4A2, NR4A3, MEIS1, ZNF593, 
ZNF516, ZNF423, ZEB1, TFAP2A, TCF21, KLF6, KLF9, JUN, 
JUNB, ESR2, FHL1, and FHL2.
Conversely to p63 the ZEB1 factor is involved in epithelial 
to mesenchymal transition in carcinogenesis, i.e., the de-
differentiation of epithelial cells[32] and is a putative prostate 
cancer biomarker.[33] It remains to be investigated how GATA3 
might interplay in prostate transcriptional networks with 
the aforementioned co-expressed factors. However, it is of 
interest that ZEB1 protein can bind in-vitro to a GATA3 gene 
silencer and can repress GATA3 in reporter gene assays, in 
the context of the Jurkat T-cell line.[34] While this needs to be 
shown in a more rigorous manner in an in-vivo context using, 
for example, chromatin immunoprecipitation of ZEB1 on the 
GATA3 regulatory element, whether this can also be shown 
in prostate is a point of significant interest. 
pS2 (TFF1) is a co-expressed gene of GATA3 in breast 
cancers.[4] Interestingly, this was again seen to be the case in 
prostate cancers. The presence of prostate pS2 has previously 
been investigated, correlating with prostate hyperplasia and 
cancer.[35,36] Although it remains to be shown, it is possible that 
pS2 may then be a common target of GATA3 in both breast 
and prostate tissues. 
However, the most frequent co-expressing gene with GATA3 
was TRIM29 (ATDC) in almost 60% of studies analyzed. 
ATDC was observed to be downregulated in cancers including 
prostate cancers,[37] and when transfected into cancer cells, 
ATDC reduced colony formation in soft agar,[38] which is 
suggestive of a tumor suppressive role. 
Altogether, the genes listed in this meta-analysis may prove to 
be most useful in future studies of GATA3 in prostate, acting 
as a “road-map” of putative pathway-partners. For example, 
GATA3 might act in co-operation with p63 in epithelial cells, 
as GATA3 itself has been shown to be important for epithelial 
terminal differentiation, albeit in the context of mammary 
glands.[39,40] 
Common GATA3 Co-expressing Genes
All of the previous meta-analyses were compared for common 
overlapping genes [Table 1]. As GATA3 co-expressed genes in 
breast cancer, using an identical technique, have already been 
reported,[4] the overlaps with these new meta-analyses are 
shown here in [Additional File 6]. 
As can be observed, only 10 genes were co-expressed with 
GATA3 in over 2 tissues (TRA@, PDE4DIP, MAL, LCK, KRT7, 
HLA-DQB1, IL32, IL15, DPYD, and CHI3L2). This low number 
reflects the concept of tissue-specific pathways of GATA3 
regulation, supported by the types of genes co-expressed with 
GATA3 within the tissues themselves (e.g., immunological 
genes in leukemias and lymphomas, transporters in the kidney 
studies). Altogether, the data not only provide evidence that 
GATA3 may be involved in distinct pathways, but also reveal 
some of these pathway partners.
Conclusions
While the in-silico meta-analysis data presented can do no more 
than imply pathway partners of GATA3 in various tissues, the 
data presented can be considered as initial leads into future 
analysis. While an in-depth meta-analysis yields much data, it can 
only scratch the surface regarding putative pathways of GATA3. 
These data also strongly imply tissue-specific functions of 
GATA3, consistent with mounting evidence from the literature. 
How GATA3 can act in such a tissue-specific manner is an issue 
that has not yet been addressed, but likely to involve unique 
tissue-specific partners and post-translational modifications, 
controlling the functions of this transcription factor. 4 4
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Table 1: Common co-expressed genes of 
GATA3 over different tissues 
 Leukemia  Lymphoma  Kidney  Prostate  Brain
TRA@  !  !     !
PDE4DIP  !  !  !  
MAL  !   !  ! 
LCK  !  !   ! 
KRT7     !  !  !
HLA-DQB1  !    !  !
IL32  !  !   ! 
IL15  !  !   ! 
DPYD  !  !   ! 
CHI3L2  !   !  ! 
CCL4  !  !    
ZEB1       !  !
ZAP70  !  !    
WARS  !  !    
TSC22D1   !   ! 
TRO  !    ! 
TRIM22  !   ! 
TRD@  !      !
TRBC1  !  !    
TRAT1  !  !    
TPM2   !   ! 
TPM1   !   ! 
TOP2A    !   !
TNFSF10   !   ! 
TNFAIP2  !    ! 
TMEM158  !    ! 
TGFBR3  !    ! 
TFAP2A     !  ! 
TARP  !  !    
SVIL  !      !
STAT5B  !  !    
STAM  !      !
SQLE  !   !  
SPOCK2  !  !    
SORBS2      !  !
SH2D1A  !  !    
SEMA3C     !  ! 
RTN1  !  !    
RGN     !  ! 
RAB25    !  ! 
QPRT  !   !  
PTPRF  !  !    
PTPRD  !      !
PTPN3  !    ! 
PRSS23  !    ! 
PRKCB1     !  ! 
PRF1  !  !    
PKIA  !      !
PIP4K2A  !      !
PELO  !  !    
PEG10     !  ! 
PARD3  !      !
NP     !  ! 
NELL2  !    ! 
MYCN  !   !  
MAST4  !    ! 
MAP3K8   !     !
MAFB  !  !    
MAF  !  !    
LTBP1   !   ! 
LEF1  !  !    
LAT  !  !    
KLRB1  !  !    
KLF6       !  !
KCNJ15     !  ! 
JUN   !   ! 
ITK  !  !    
ITGA1  !    ! 
IL7R  !  !    
IL2RB  !  !    
 Leukemia  Lymphoma  Kidney  Prostate  Brain
IL1RL1    !   !
IFITM2  !    ! 
IER3   !   ! 
ID2   !   ! 
HPGD  !   !  
HLA-DPA1  !    ! 
HLA-B   !   ! 
GZMK  !  !    
GZMB  !  !    
GZMA  !  !    
GSN  !   !  
GNPDA1  !  !    
GNLY  !  !    
GLS   !  !  
GBP1  !  !    
GAS1       !  !
GABARAPL1     !  ! 
FYN  !  !    
FYB   !  !  
FLT3LG  !  !    
FGL2  !    ! 
FER1L3      !  !
FAS  !    ! 
EPS8   !   ! 
EPHX2  !   !  
EPHA3      !  !
EPB41L3  !    ! 
ENPP2  !  !    
ENG   !  !  
DUSP6   !   ! 
DUSP4   !   ! 
DMD  !    ! 
DIP2C  !      !
DDR2   !   ! 
CYP2B6  !  !  
CYP27A1   !   ! 
CTSW  !  !    
CTSB   !   ! 
COL4A3    !  ! 
CLEC2B  !   ! 
CG018   !   ! 
CD8B  !  !    
CD8A  !  !    
CD7  !  !    
CD6  !  !    
CD5  !  !    
CD3G  !  !    
CD3E  !  !    
CD3D  !  !    
CD28  !  !    
CD247  !  !    
CD2  !  !    
CCR7  !  !    
CCND2  !   ! 
CCND1  !     !
CCL5  !  !    
CAPN2  !  !    
CAMK4  !   !  
BCL11B  !  !    
ATF3   !   ! 
ARL4C  !  !    
AQP3  !    ! 
ANXA1  !    ! 
ANK3  !      !
ANGPT1  !    ! 
AKR1C2  !      !
AIF1  !   !  
Genes were compared over the different meta-analyses. ! shows that this gene is 
represented.5 5
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In conclusion, the data presented reveal many novel findings 
regarding putative pathways within which GATA3 might act 
and support the hypothesis that GATA3 acts in a tissue-specific 
manner, while retaining its common function in differentiation 
and development. 
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